As always, supplements should be integrated into a comprehensive care plan under medical supervision to ensure they align with individual health needs and do not interact with existing pharmaceutical regimens
The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia
CagriSema is two separate moleculessemaglutide (GLP-1 agonist) plus cagrilintide (amylin analog)combined in one injection
In sterile water or saline (no preservative): Use promptly or freeze in aliquots
CagriSema cagrilintide 2.4 mg plus semaglutide 2.4 mg was submitted to the FDA on 18 December 2025 for chronic weight management, with the agency expected to review it during 2026
Injections are advised to circumvent potential absorption challenges in the gastrointestinal tract, particularly for those with known issues like Crohn's disease or irritable bowel syndrome, providing a more immediate replenishment compared to oral supplements, which may not be fully absorbed